The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

The White House has secured another deal with major pharmaceutical companies, this time to offer popular weight loss drugs for less in some cases. On Thursday, the administration announced from the Oval Office that,

A deal with drugmakers also means that Medicare would cover obesity drugs for the first time. But certain limitations persist.

Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will be available at reduced prices,

The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have access to them under two deals announced Thursday by the Trump administration.

TrumpRx will offer Novo Nordisk's Ozempic and Wegovy through TrumpRx for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.

Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying competition and pricing pressure” led it to lower its yearly sales projections.